Surrozen, Inc. (SRZNW) Stock Analysis

Company Overview

Surrozen, Inc. operates as a biotechnology company dedicated to the discovery and development of drug candidates designed to selectively modulate the Wnt pathway for tissue repair. The company's primary focus involves creating antibody-based therapeutics that target various disease areas, including conditions affecting the intestine, liver, retina, cornea, and lung. Regarding its sector and industry classification, the available data indicates that the company's specific sector and industry are listed as N/A, which suggests a specialized positioning within the broader biotechnology landscape that may not fit into standard industry categorizations used by major financial data providers. In terms of scale, the company reports a market cap of N/A and an annual revenue of $3.48M, while the employee count is also listed as N/A. The absence of a quantifiable market cap figure combined with a relatively modest revenue stream of $3.48M indicates that the company is likely in an early-stage development phase or is a small-cap entity where traditional valuation metrics have not yet stabilized. The lack of disclosed employee data further underscores the company's current operational scale, suggesting that resources are heavily concentrated in R&D activities rather than large-scale commercial infrastructure at this time.

Financial Health

The company reported a revenue of $3.48M for the trailing twelve months, yet it posted a net income of $-242,026,000 and an EBITDA of $-41,555,000, revealing a significant divergence between top-line activity and bottom-line profitability. This substantial gap between the $3.48M revenue and the massive negative net income indicates a cost structure where expenses, likely driven by high research and development costs or clinical trial expenditures, far exceed the revenue generated by the lead product candidates. Free cash flow stands at $-16,856,500, which implies that the company is burning cash rapidly and lacks the immediate financial flexibility to fund operations without external capital injections. The margin analysis reveals a gross margin of 0.0%, an operating margin of -2393.8%, and a profit margin of 0.0%, all of which highlight the extreme financial pressure the company faces as its costs dwarf its sales, resulting in a complete inability to cover operating expenses with current revenue. The company holds $89.25M in cash against $6.64M in debt, providing a substantial liquidity buffer despite the current operational losses. While the debt-to-equity ratio is listed as N/A due to lack of equity data, the absolute debt level of $6.64M is negligible compared to the cash reserves, suggesting a balance sheet that is not currently leveraged in a distress manner. The current ratio is reported at 9.22, which indicates a very strong short-term liquidity position where current assets significantly exceed current liabilities, allowing the company to comfortably meet its short-term obligations. Return on Equity is listed as N/A, while Return on Assets is -35.7%, indicating that the asset base is currently generating negative returns relative to the capital invested.

Valuation Assessment

The trailing P/E ratio and forward P/E are both listed as N/A, which is expected for a company with significant negative earnings and prevents the application of traditional earnings-based valuation multiples. The price-to-book ratio is reported as -0.00, a figure that indicates the market capitalization is so low relative to the book value, or that the negative net income has pushed the valuation metrics into a state where they do not reflect a standard market premium over book value. Price-to-sales and EV/EBITDA are also N/A, suggesting that alternative valuation metrics relying on positive earnings or normalized sales multiples are not applicable given the company's current financial trajectory. The 52-week high and low are both recorded at $0.02, meaning the stock is currently trading at 0% relative to this range, as the price has not moved above or below this threshold during the measurement period. The beta value is 0.56, which indicates that the stock's price volatility is approximately 44% lower than the broader market, suggesting that the share price is less sensitive to general market fluctuations compared to large-cap equities.

Growth & Income

Revenue growth year-over-year is -19.4%, while earnings growth is listed as N/A due to the absence of profitable earnings in the prior period for comparison. The negative revenue growth indicates a contraction in sales, and since the company has no earnings, there is no scenario where earnings are growing faster or slower than revenue in a traditional sense; rather, the company is facing challenges in expanding its top line. As a non-dividend payer with a dividend yield of N/A and a payout ratio of N/A, the company reinvests its limited resources, if any, directly into growth initiatives such as clinical trials and drug development rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, reflecting the typical characteristics of a biotechnology firm in the pre-revenue or early commercialization stage where capital preservation and product development take precedence over shareholder distributions.